Progression to adenocarcinoma in Barrett's Esophagus after liver transplantation

Transplantation

Volumn 91, Issue 11, 2011, Pages 1250-1253

  Oezcelik, Arzu ^a   Kaiser, Gernot M ^a   Dechêne, Alexander ^a   Treckmann, Juergen W ^a   Sotiropoulos, Georgios C ^a   Reinhardt, Renate ^a   Saner, Fuat H ^a   Paul, Andreas ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Barrett's esophagus; Esophageal cancer; Premalignant lesion; Transplantation

Indexed keywords

CISPLATIN; CYCLOSPORIN A; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS RESECTION; FEMALE; GRAFT REJECTION; HUMAN; LIVER TRANSPLANTATION; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 79958287471     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821841a0     Document Type: Article

References (24)

1. Karam VH, Gasquet I, Delvart V, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 2003; 76: 1699.
2. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80: S254.
3. Sheiner PA, Magliocca JF, Bodian CA, et al. Long-term medical complications in patients surviving>or=5 years after liver transplant. Transplantation 2000; 69: 781.
4. Fung JJ, Jain A, Kwak EJ, et al. De novo malignancies after liver transplantation: A major cause of late death. Liver Transpl 2001; 7: S109.
5. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: A nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221.
6. DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: Fifty years of controversy. Ann Surg 2000; 231: 303.
7. Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995; 332: 19.
8. Timmons CF, Dawson DB, Richards CS, et al. Epstein-Barr virusassociated leiomyosarcomas in liver transplantation recipients. Origin from either donor or recipient tissue. Cancer 1995; 76: 1481.
9. Kelly DM, Emre S, Guy SR, et al. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 1998; 83: 1237.
10. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530.
11. Alamartine E, Sabido O, Berthoux F. In-vitro effects of cyclosporin A, FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells. Nephrol Dial Transplant 1994; 9: 1456.
12. Tamura F, Masuhara A, Sakaida I, et al. FK506 promotes liver regeneration by suppressing natural killer cell activity. J Gastroenterol Hepatol 1998; 13: 703.
13. Engl T, Makarevic J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: Impact on tumor recurrence and malignancy. BMC Cancer 2005; 5: 4.
14. Leckel K, Beecken WD, Jonas D, et al. The immunosuppressive drug mycophenolate mofetil impairs the adhesion capacity of gastrointestinal tumour cells. Clin Exp Immunol 2003; 134: 238.
15. Campistol JM. [Minimizing the risk of cancer in transplant patients].G Ital Nefrol 2020; 27(suppl 50): S81.
16. Ravaud A, Bernhard JC, Gross-Goupil M, et al. [mTOR inhibitors: Temsirolimus and everolimus in the treatment of renal cell carcinoma]. Bull Cancer 2010; 97: 45.
17. Chapman JR, Webster AC. Cancer after renal transplantation: The next challenge. Am J Transplant 2004; 4: 841.
18. Presser SJ, Schumacher G, Neuhaus R, et al. De novo esophageal neoplasia after liver transplantation. Liver Transpl 2007; 13: 443.
19. Trotter JF, Brazer SR. Rapid progression to high-grade dysplasia in Barrett's esophagus after liver transplantation. Liver Transpl Surg 1999; 5: 332.
20. Yao F, Ahuja J, Savides T, et al. Rapid progression of gastroesophageal junction adenocarcinoma after liver transplantation. J Clin Gastroenterol 1997; 24: 54.
21. Phillips RW, Wong RK. Barrett's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin North Am 1991; 20: 791.
22. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57: 1200.
23. Abate E, DeMeester SR, Zehetner J, et al. Recurrence after esophagectomy for adenocarcinoma: Defining optimal follow-up intervals and testing. J Am Coll Surg 2010; 210: 428.
24. Pennathur A, Luketich JD, Landreneau RJ, et al. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg 2008; 85: 1930; discussion 1936.